Dr. Misrai et al. draws attention to obstructive sleep apnea syndrome (OSAS) as an under-recognized entity that can lead to nocturia. They correctly state that if OSAS is present, the initial management would usually not be a pharmacological treatment. Although we did not use a validated screening tool such as the Berlin Questionnaire, taking a sleep history is standard for our nocturia evaluation. In our retrospective cohort of 403 diverse patients, we found that a history of sleep disorder was associated with higher baseline nocturia events. The retrospective nature and method of identifying patients may inherently lead to a lower rate of OSAS, as patients who were felt to have had another underlying medical condition (i.e., OSAS) may have left the visit with a diagnosis code of something other than nocturia. While it is possible that some in our cohort had undiagnosed sleep apnea, only 8.4% of our population was obese and most patients were female (59%). Male gender and obesity are consistently recognized risk factors [1, 2] , only 8.4% of our population was obese and most patients in our cohort were female (59%). When studying nocturia, we should realize that practice patterns (such as an emphasis on primary care screening or access to specialist care) may influence the patients who are included in a single-center study.
Interestingly, if we consider the large multicenter studies of the newly formulated desmopressin in patients with nocturia, subjects were excluded if they had the diagnosis of OSAS, but routine screening for OSAS with a validated questionnaire was not included in the methods they present. In spite of this, patients had an improvement in their symptoms and quality-of-life measures [3] .
